Mandate

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").

The facility is located in Strängnäs and provides specialised expertise and comprehensive services, supporting the development and manufacturing of oral solids and with specialist infrastructure for beta-lactam production. APL, which is now acquiring the facility, is a wholly state-owned company with a social mission to develop and provide a medically appropriate and quality-assured range of extemporaneous medicines and stock preparations. The acquisition is an important step for the Swedish government in strengthening Sweden's preparedness and ensuring access to essential medicines in Sweden, particularly in crisis situations.

Read more on the Government's website here.

Vinge's team consisted of among others Jonas Bergström, Per Kling and Ellenor Eckerborn (M&A), Mathilda Persson and Siri Blomberg (Corporate Commercial), Åsa Hellstadius and Ian Jonson (Life Science).

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026